Novo Nordisk Stock Rises Ahead of Data on Ozempic Ingredient’s Ability to Lower Heart Risk | Global News Avenue

Novo Nordisk(NGOs) On Monday, the company said it will introduce the ability to reduce heart risk by Semaglutide, its weight loss medication and the ability of Wegovy’s active ingredient to reduce heart risk.

Danish drug developers plan to attend the American Academy of Cardiology and Expo, which will be held from March 29 to 31. Its speech “will provide new information on diligent peptide drugs to reduce cardiovascular risk, focusing on diseases including type 2 diabetes, obesity, peripheral artery disease and chronic kidney disease.

Novo Nordisk shares rose more than 3% in intraday trading on Monday, recouping some of their losses last week Disappointing results In a 3-stage trial of its internal weight loss medication. Novo reported that the average weight loss for patients taking the drug was 15.7% of their weight after 68 weeks, while the drugmaker reportedly targeted 25%.

Despite Monday’s earnings, Novo Nordisk’s stock has fallen about 7% in the year so far and has lost 40% of its value in the past 12 months.